PeerJ

Prediction model of emergency mortality risk in patients with acute upper gastrointestinal bleeding: a retrospective study

Lan Chen¹, Han Zheng² and Saibin Wang³

- ¹ Nursing Education Department, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua Municipal Central Hospital, Jinhua, ZheJiang, China
- ² Emergency Department, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua Municipal Central Hospital, Jinhua, ZheJiang, China
- ³ Department of Respiratory Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua Municipal Central Hospital, Jinhua, ZheJiang, China

ABSTRACT

Background: Upper gastrointestinal bleeding is a common presentation in emergency departments and carries significant morbidity worldwide. It is paramount that treating physicians have access to tools that can effectively evaluate the patient risk, allowing quick and effective treatments to ultimately improve their prognosis. This study aims to establish a mortality risk assessment model for patients with acute upper gastrointestinal bleeding at an emergency department.

Methods: A total of 991 patients presenting with acute upper gastrointestinal bleeding between July 2016 and June 2019 were enrolled in this retrospective single-center cohort study. Patient demographics, parameters assessed at admission, laboratory test, and clinical interventions were extracted. We used the least absolute shrinkage and selection operator regression to identify predictors for establishing a nomogram for death in the emergency department or within 24 h after leaving the emergency department and a corresponding nomogram. The area under the curve of the model was calculated. A bootstrap resampling method was used to internal validation, and decision curve analysis was applied for evaluate the clinical utility of the model. We also compared our predictive model with other prognostic models, such as AIMS65, Glasgow-Blatchford bleeding score, modified Glasgow-Blatchford bleeding score, and Pre-Endoscopic Rockall Score.

Results: Among 991 patients, 41 (4.14%) died in the emergency department or within 24 h after leaving the emergency department. Five non-zero coefficient variables (transfusion of plasma, D-dimer, albumin, potassium, age) were filtered by the least absolute shrinkage and selection operator regression analysis and used to establish a predictive model. The area under the curve for the model was 0.847 (95% confidence interval [0.794–0.900]), which is higher than that of previous models for mortality of patients with acute upper gastrointestinal bleeding. The decision curve analysis indicated the clinical usefulness of the model. **Conclusions:** The nomogram based on transfusion of plasma, D-dimer, albumin, potassium, and age effectively assessed the prognosis of patients with acute upper gastrointestinal bleeding presenting at the emergency department.

Submitted 19 February 2021 Accepted 31 May 2021 Published 24 June 2021

Corresponding author Saibin Wang, saibinwang@hotmail.com

Academic editor Chih-Chung Shiao

Additional Information and Declarations can be found on page 15

DOI 10.7717/peerj.11656

Copyright 2021 Chen et al.

Distributed under Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Emergency and Critical Care, Evidence Based Medicine, Gastroenterology and Hepatology, Nursing

Keywords Acute upper gastrointestinal bleeding, Prognosis, Nomogram, Emergency care, Mortality risk

INTRODUCTION

Acute upper gastrointestinal bleeding (AUGIB) is a common presentation at emergency departments (EDs), with hematemesis, melena, and syncope representing as the major symptoms. Although the survival rate of patients with AUGIB has improved with advances in drug therapy and endoscopic diagnosis and treatment, it remains a potentially life-threatening gastrointestinal emergency (*Balaban et al., 2014*). It is paramount that treating physicians have access to tools that can effectively evaluate the patient risk, allowing quick and effective treatments to ultimately improve their prognosis (*Balaban et al., 2014*; *Barkun et al., 2019*).

Several previous models have been developed to estimate the mortality risk of patients with UGIB, such as the Glasgow-Blatchford score (GBS), Rockall score (RS), and the AIMS65 score (Rockall et al., 1996; Blatchford, Murray & Blatchford, 2000; Saltzman et al., 2011; Gaduputi et al., 2014; Abougergi et al., 2016). However, existing predictive models are not commonly used in clinical care for various reasons. First, some of these models require endoscopic information that is not readily available at the time of presentation. However, given the availability of endoscopy, the use of either GBS, modified GBS (mGBS), Pre-Endoscopic RS (PERS), or AIMS65 score is currently recommended, as these models are based on data that are easy to acquire. For example, GBS includes the measurement of systolic blood pressure (SBP), hemoglobin (HB), blood urea nitrogen (BUN), albumin, and international normalized ratio (INR), pulse, as well as evaluation of the presence of symptoms such as melena, syncope and liver disease, and heart failure, while PERS considers age, state of shock, and concomitant disease. Second, recent studies have found inconsistent results when using these models (Yaka et al., 2015; Budimir et al., 2016; Martinez-Cara et al., 2016; Park et al., 2016; Stanley et al., 2017; Zhou et al., 2017; Tang et al., 2018; Kim, Choi & Shin, 2019; Robertson et al., 2020). Third, it is difficult to obtain a personalized mortality assessment from these systems. More recently, Zhou et al. developed a prognostic nomogram for cirrhosis patients with UGIB admitted to intensive care units that they named upper gastrointestinal bleeding-chronic liver failure-sequential organ failure assessment (UGIB-CLIF-SOFA) (Zhou et al., 2017). However, as cirrhosis accounts only for a subset of patients with UGIB, the use of this model is limited. Moreover, the type of clinical intervention administered is an important factor affecting patients' prognosis. To the best of our knowledge, a prognostic model that includes patient characteristics and clinical interventions as risk factors affecting prognosis remains to be developed. In addition, no current prognostic model can predict individual level mortality probability for patients with AUGIB presenting at EDs.

Various factors influence the prognosis of patients with AUGIB, including primary disease, volume and site of bleeding, age and intervention administered at the time of admission (*Lahiff et al., 2012; Ko et al., 2017; Barkun et al., 2019*). Data on bleeding-related

factors, such as details of the site, cause, or type of bleeding, are difficult to obtain for patients treated in emergency care. The extent of bleeding should be ascertained on the basis of the patient's chief complaint, vital signs, and laboratory test results. The aim of this study was to develop a model to predict the mortality of individual patients presenting at EDs, based on routinely collected, objective parameters, and clinical interventions administered. The model is accompanied by a nomogram.

MATERIALS & METHODS

Research design

This was a retrospective cohort study of consecutive patients with AUGIB treated at an ED between July 2016 and June 2019. The Ethics Committee of Jinhua Municipal Central Hospital approved this study (No.16–32). The data were anonymous, and the requirement for informed consent was therefore waived. The study adhered to the principles of the Declaration of Helsinki.

Study population

The medical records were used to recognize participants. Patients older than 18 years of age who had hematemesis (or bloody nasogastric aspirate), melena, or both, as confirmed by the hospital staff, were considered for inclusion (*Villanueva et al., 2013*). Patients were excluded from the present study if they sought treatment for melena but are diagnosed with lower gastrointestinal bleeding. A total of 991 patients were included in this study.

Data collection

Structured data extraction forms were used by trained researchers for data collection. Medical record review and data extraction were performed by nursing staff with >10 years of experience at the ED. Following data extraction, quality control was performed on randomly selected data subsets. The following data were extracted: age (years), gender, chief complaints (syncope, hematemesis, melena), first effective vital signs and pulse oxygen saturation (%; in room air) obtained at the time of emergency admission, laboratory tests of blood, comorbidities, type of blood transfusion (mL), endoscopic reports, and survival status at discharge from ED (death in ED or within 24 h after leaving the ED). AIMS65, GBS, mGBS, and PERS were calculated for every patient based on the first available data. At the study site, the first vital signs are recorded in the emergency triage system, which constitutes part of the electronic medical records. Data on blood test results and clinical interventions can also be accessed through electronic medical records.

Statistical analysis

Data were analysised as previously described in *Wang*, Tu
otin Dong (2019), especially the process of model building and model validation. We used descriptive statistics to summarize the patients' baseline characteristics. For categorical variables, counts (percentages) were reported, while for continuous variables, mean \pm standard deviation (SD) or median (interquartile) were reported. Comparisons of parameters between



survivors and non-survivors were performed using Student's t-test and the Mann-Whitney U test for continuous variables with or without a normal distribution and using the χ^2 -test for categorical variables. The least absolute shrinkage and selection operator (LASSO) regression, which is suitable for the regression of high-dimensional data (Huang et al., 2016), was used for predictor selection and regularization. Logistic regression analysis was used to establish a model predicting death in ED or within 24 h after leaving the ED, and a nomogram was constructed on the basis of this model. The area under the curve (AUC) was calculated to evaluate the discrimination performance of the model and a 1,000 bootstrap method was applied for internal validation. For further validation, enrolled patients were randomly divided into two groups, 50% for training and 50% for validating. Statistical differences in the AUCs were compared using the method of DeLong. Decision curve analysis (DCA) was performed to evaluate the model's clinical utility by quantifying the net benefits at different threshold probabilities (Vickers et al., 2008). Furthermore, we calculated the AUC and DCA to evaluate the predictive performance of the nomogram in undergoing and not undergoing endoscopy subgroup. The predictive performances of the nomogram, AIMS65, GBS, mGBS, and PERS were compared by AUC and net reclassification improvement (NRI). Statistical analysis was conducted using EmpowerStats (www.empowerstats.com) and R 3.5.1 (www.r-project.org). P-values < 0.05 were considered statistically significant.

RESULTS

A total of 1,008 patients were initially recruited into the study and 991 remained after the exclusion criteria were applied (Fig. 1).

Table 1 presents the patient characteristics and types of clinical interventions administered. Among the 991 patients, 41 (4.14%) died in ED or within 24 h after leaving the ED. Univariate analysis showed that death in ED occurred more frequently in patients with low red blood cell (RBC) count, hematocrit (HCT), HB, platelet (PLT) count,

albumin (ALB), albumin/globulin ratio (A/G), total protein, in patients with high C-reactive protein (CRP), prothrombin time (PT), D-dimer, INR, glutamic oxaloacetic transaminase (AST), serum creatinine, in patients with chronic liver diseases, in patients with lower pulse oxygen saturation and in patients receiving plasma transfusion.

Among the 42 collected variables shown in Table 1, included age, gender, chief complaints, first effective vital signs and pulse oxygen saturation, laboratory tests of blood, comorbidities, type of blood transfusion, five were filtered on the basis of non-zero coefficients calculated by the LASSO regression analysis using the minimum criteria (Fig. 2). These variables were transfusion of plasma, D-dimer, albumin, potassium, and age. We constructed a mortality risk prediction model based on the aforementioned five predictors (Table 2). The AUC for the predictive model was 0.847 (95% confidence interval (CI) [0.794–0.900]), whereas the AUC for the internal validation model was 0.858 (95% CI [0.806–0.898]) (Fig. 3). The AUC for training group and validating group was 0.839 and 0.838, respectively (Fig. S1). The AUC of this model was also greater than that of the four other models (Table 3). We then calculated continuous NRI for the nomogram and four other models for death in ED or within 24 h after leaving the ED. The results also show that the nomogram was superior to other models (Table S1). The corresponding nomogram is presented in Fig. 4. The AUC for undergoing and not undergoing endoscopy subgroup was 0.874 and 0.822, respectively (Fig. S2).

The calibration curve of the predictive model showed a good fit between the predicted risk of death and observed outcomes in patients with AUGIB (Fig. 5). The decision curve (Fig. 6) demonstrated that this model, by helping assess the risk of death in ED and informing interventions, improved patient outcomes compared with either treat-all or treat-none strategies. Specifically, when the model assessed the risk of death in ED as within 3–76%, the benefits of this model to patient outcomes were most robust.

DISCUSSION

This study proposed a novel and easy-to-use model for predicting death in ED or death within 24 h after leaving the ED of patients with AUGIB. This model combined five predictors selected by LASSO regression: transfusion of plasma, D-dimer, albumin, potassium, age. Based on patients' characteristics and clinical interventions, all five predictors were readily accessible at EDs. Our nomogram may be used to infer the risk of mortality and therefore aid in the screening of patients with AUGIB who are at high risk. Thus, this could be a useful aid for physicians in determining a treatment regime. The model showed a good discriminatory ability of 0.847 (95% CI [0.794–0.900]). Moreover, it showed potential clinical usefulness. Although the calibration curve showed that among patients with actual mortality of great than 8%, the model overestimated mortality risk by 4% or greater, which may cause the waste of medical resources, it also would likely promote the active and efficient management of emergency patients.

The ability to quickly identify and appropriately treat patients at high risk is paramount in emergency care. Infusion of large plasma volumes was associated with poor survival outcomes (*Subramaniam et al., 2016*). Patients who received freshly frozen plasma transfusions had significantly greater rates of overall complications, acute respiratory

Table 1 Baseline demographic and clinical characteristics of the study participants.

Variable	Death in emergency department			
	No $(n = 950)$	Yes $(n = 41)$		
Baseline characteristics				
Sex, <i>n</i> (%)			0.119	
Male	682 (71.8%)	34 (82.9%)		
Female	268 (28.2%)	7 (17.1%)		
Age (years)	64.6 ± 16.4	69.4 ± 13.4	0.065	
Monitoring parameters at admission				
Temperature (degrees Celsius)	36.6 ± 0.8	36.2 ± 1.3	0.123	
HR (beat/min)	94.5 ± 20.0	96.1 ± 27.6	0.620	
SBP (mmHg)	120.0 ± 25.6	114.5 ± 34.9	0.179	
DBP (mmHg)	66.1 ± 17.5	65.6 ± 30.2	0.095	
Pulse oxygen saturation (%)	96.8 ± 5.9	89.1 ± 22.1	< 0.001	
Chief complaints, <i>n</i> (%)				
Syncope			0.198	
No	913 (96.1%)	41 (100.0%)		
Yes	37 (3.9%)	0 (0.0%)		
Hematemesis			0.177	
No	630 (66.3%)	23 (56.1%)		
Yes	320 (33.7%)	18 (43.9%)		
Melena			0.880	
No	222 (23.4%)	10 (24.4%)		
Yes	728 (76.6%)	31 (75.6%)		
Blood test				
RBC (10 ¹² /L)	3.1 ± 1.0	2.5 ± 0.9	< 0.001	
HCT (%)	27.3 ± 9.0	23.2 ± 7.1	0.005	
HB (g/L)	89.4 ± 32.9	74.4 ± 23.8	0.004	
PLT (10 ⁹ /L) Median (Q1–Q3)	173.0 (100.0-244.0)	106.0 (73.0–157.0)	0.001	
CRP (mg/L) Median (Q1–Q3)	5.4 (2.0-20.4)	17.9 (3.0-44.7)	0.024	
PT (s) Median (Q1–Q3)	13.0 (11.9–15.3)	18.1 (14.1–23.0)	0.007	
D-dimer (µg/L) Median (Q1–Q3)	726.5 (320.0–2066.2)	3062.0 (1018.5-6258.5)	< 0.001	
INR Median (Q1–Q3)	1.1 (1.0–1.3)	1.6 (1.3–2.0)	< 0.001	
ALT (IU/L) Median (Q1–Q3)	18.9 (11.7–30.9)	28.5 (10.1–65.8)	0.105	
AST (IU/L) Median (Q1-Q3)	26.6 (19.1–46.5)	46.4 (27.2–185.2)	< 0.001	
Blood amylase (U/L) Median (Q1–Q3)	58.0 (43.0-81.0)	55.5 (39.0–112.5)	0.992	
Potassium (mmol/L)	4.1 ± 0.7	4.9 ± 1.3	< 0.001	
BUN (mg/dl)	11.8 ± 7.4	12.8 ± 7.3	0.428	
Serum creatinine (µmol/L) Median (Q1–Q3)	96.0 (79.0-120.1)	140.5 (114.8–207.6)	< 0.001	
ALB (g/L)	31.6 ± 6.5	25.8 ± 5.8	< 0.001	
A/G	1.1 ± 0.3	1.0 ± 0.3	0.018	
Total protein (g/L)	61.3 ± 10.6	53.7 ± 13.0	< 0.001	

Table 1 (continued)

No (n = 950) Yes (n = 41) Blood glucose (mmol/L) Median (Q1–Q3) 7.7 (6.5–10.0) 8.7 (6.3–11.1) 0.447 PH 7.4 ± 0.1 7.2 ± 0.3 <0.001 Lactic acid (mmol/L) 5.5 (1.2–4.6) 1.21 (3.4–18.5) <0.001 Base exces (mmol/L) -3.6 (-6.3–0.3) -1.4.8 (-24.7–-3.4) <0.001 Intervention measures - 0.157 <0.600 Transfasion of red blood cells, n (%) 19.0 (0-2.70) 14.0 (7.0–2.50) 0.660 Transfasion of red blood cells (m1) Median (Q1–Q3) 2.9 (0.0–4.0) 3.7 (0.0–6.0) 0.666 Transfasion of red blood cells (m1) Median (Q1–Q3) 2.9 (0.0–4.0) 3.7 (0.0–6.0) 0.066 Transfasion of plasma, n (%) - - 0.001 Transfasion of plasma, n (%) - 0.001 No 642 (67.6%) 15 (3.6.%) - 0.001 Transfasion of plasma (n1) Median (Q1–Q3) 3.08 (2.2.%) 2.6 (3.4%) - 0.001 Transfasion of plasma (n1) Median (Q1–Q3) 3.08 (2.4%) 3.8 (92.7%) - 0.0010 Transfasion of	Variable	Death in emergency depa	Р		
Blood glucose (mmol/1) Median (Q1-Q3) 7,7 (6.5-10.0) 8,7 (6.3-11.1) 0,847 PH 7.4 ± 0.1 7.2 ± 0.3 <0.001 Lactic acid (mmol/1) 3,5 (1.2-4.6) 1.21 (3.4-18.5) <0.001 Base eccess (mmol/1) -36 (-6.3-3) 1-14.8 (-24,73.4) <0.001 Intervention measures 0.460 Transfusion of red blood cells, n (%) 12 (29,3%) 0.450 Yes 567 (59,7%) 29 (70,7%) Yes 567 (59,7%) 29 (70,7%) Transfusion of red blood cells (ml) Median (Q1-Q3) 383 (40,3%) 12 (29,3%) Transfusion of red blood cells (ml) Median (Q1-Q3) 383 (26,7%) 29 (70,7%) Transfusion of plasma (ml) Median (Q1-Q3) 153.7 (00-200.0) 273.2 (0.0-400.0) <0.001 Transfusion of plasma (ml) Median (Q1-Q3) 153.7 (00-200.0) 273.2 (0.0-400.0) <0.001 Transfusion of plastelets, n (%) 153.7 (00-200.0) 273.2 (0.0-400.0) <0.001 Yes 163 (79,8%)		No $(n = 950)$	Yes $(n = 41)$	0.847	
Pf74 ± 0.17.2 ± 0.3<0.001Lactic add (mmol/L)3.5 (1.2-4.6)(2.1 (3.4-18.5)<0.001	Blood glucose (mmol/L) Median (Q1–Q3)	7.7 (6.5–10.0)	8.7 (6.3-11.1)		
Lack acid (mmol/L)35, (12-4.6)12, (1,4-18.5)4,000Base coses (mmol/L)-6,6-0.3)-14, (2-4,73.4)4,000Latervation measuresEmergency observation time (h) Median (Q1-Q3)10,00,0-27.0)14,07,0-25.0)4,060Transfusion of red blood cells, n(%)56 (59,7%)29 (20,7%)-No65 (59,7%)29 (70,7%)0,066Transfusion of red blood cells (ml) Median (Q1-Q3)29 (0,0-4.0)3,7 (0,0-6.0)0,066Transfusion of plasma, n(%)24 (67,6%)15 (56,6%)-No642 (67,6%)15 (56,6%)Yes080 (32,1%)22 (0,0-0,0.0)4,001Transfusion of plasma (nl) Median (Q1-Q3)819 (0,4%)38 (22,7%)-Yes080 (32,1%)23 (20,-00,0.0)Yes15 (54%)38 (20,7%)No640 (67,6%)38 (22,7%)Yes11 (9,0%)3 (7,3%)Yes91 (9,0%)40 (97,6%)Yes91 (9,0%)10 (3,7%)No10 (20,7%)10 (20,7%)Yes10 (20,7%)10 (20,7%)Yes10 (20,7%)10 (20,7%)Yes10 (20,7%)10 (20,7%)Yes10 (20,7%)10 (20,7%)Yes10 (20,7%)10 (20,7%)Yes10 (20,7%)10 (20,7%)-<	PH	7.4 ± 0.1	7.2 ± 0.3	< 0.001	
Base exces (mmol/1)-3.6 (-6.3-0.3)-14.8 (-24.73.4)<0001Intervention messuresEmergency observation time (h) Median (Q1-Q3)19.0 (9.0-27.0)14.0 (7.0-25.0)0.600Transfasion of red blood cells, n (%)38.3 (40.3%)12.(29.3%)15.7NoS67 (59.7%)29.00-40.03.7 (0.0-6.0)0.060Transfasion of red blood cells (ml) Median (Q1-Q3)2.9 (0.0-40.0)3.7 (0.0-6.00)0.060Transfasion of plasma, n (%)0.63 (2.6%)3.6 (3.4%)0.001Yes0.60 (3.2.4%)2.6 (3.4%)0.001Transfasion of plasma (ml) Median (Q1-Q3)0.50 (2.0.4%)2.6 (3.4%)0.001Transfasion of plasma (ml) Median (Q1-Q3)0.50 (2.0.4%)2.6 (3.4%)0.001Transfasion of plasma (ml) Median (Q1-Q3)0.51 (2.0.4%)0.0010.001Transfasion of plastels, n (%)3.6 (2.7%)3.6 (2.7%)0.001Yes0.91 (9.6%)3.6 (2.7%)0.0011.0.1%Yes0.91 (9.6%)3.6 (2.7%)1.0.1%1.0.1%Yes0.92 (9.0.4%)1.0.2%)1.0.1%1.0.1%Yes0.92 (9.0.4%)1.0.2%)1.0.1%1.0.1%Yes0.92 (9.0.4%)1.0.2%)1.0.1%1.0.1%Yes0.92 (9.0.4%)1.0.2%)1.0.1%1.0.1%Yes0.92 (9.0.4%)1.0.2%)1.0.1%1.0.1%Yes0.92 (9.0.4%)1.0.2%)1.0.1%1.0.1%Yes0.92 (9.0.4%)1.0.2%)1.0.1%1.0.1%Yes <t< td=""><td>Lactic acid (mmol/L)</td><td>3.5 (1.2-4.6)</td><td>12.1 (3.4–18.5)</td><td>< 0.001</td></t<>	Lactic acid (mmol/L)	3.5 (1.2-4.6)	12.1 (3.4–18.5)	< 0.001	
Intervention measuresUEmergony observation time (h) Median QI-Q3)19.00-027.0)14.07-0.5.0)40.40Transfusion of red blood cells, n (%)381.40.3%)12.02.3%)15.02Yes63.00.0%)20.07.0%)0.000.00Transfusion of plasma, n (%)29.00-4.0037.00-0.000.00Transfusion of plasma, n (%)642.07.5%)15.03.6.%)10.00Yes0.02.0.0%)20.00-0.000.000.00Transfusion of plasma, n (%)25.20.0-0.00.00.000.00Transfusion of plasma (n QI-Q3)0.52.0.0.00.000.00Transfusion of plasma (n QI-Q3)0.52.0.0.00.000.00Transfusion of plasma (n QI-Q3)0.52.0.0.00.000.00Transfusion of plasma (n QI-Q3)0.904.0%36.02.7%)0.00Transfusion of platelets, n (%)10.4%31.00.0.0.010.00.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0	Base excess (mmol/L)	-3.6 (-6.3-0.3)	-14.8 (-24.73.4)	< 0.001	
<table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container>	Intervention measures				
Transfusion of red blood cells, n (%)9.8 (0.3%)9.1 (2.9.3%)No3.8 (0.3%)2.9 (0.7%)0.00Transfusion of red blood cells (ml) Median (Q1-Q3)2.9 (0.0-0,0)3.7 (0.0-0,0)0.00Transfusion of plasma, n (%)2.9 (0.0-0,0)3.6 (0.3,%)1.00Transfusion of plasma, n (%)6.0 (3.0,%)3.6 (0.3,%)0.00Transfusion of plasma (ml) Median (Q1-Q3)0.802,0%)0.0013.002,0%)0.001Transfusion of cryoprecipitate, n (%)1.5 (0.0,0%)3.0 (2.9,%)0.001Transfusion of cryoprecipitate, n (%)3.1 (0.0,0%)3.0 (2.9,%)0.001Yea1.9 (0.9,%)3.0 (0.9,%)0.0 (0.9,%)0.0 (0.9,%)No1.0 (0.9,%)1.0 (0.9,%)0.0 (0.9,%)0.0 (0.9,%)Yea1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)0.0 (0.9,%)Yea1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)0.0 (0.9,%)No1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)Yea1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)No1.0 (0.0,%)1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)No1.0 (0.0,%)1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)Yea1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)No1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)No1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)No1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%)1.0 (0.9,%) <td>Emergency observation time (h) Median (Q1-Q3)</td> <td>19.0 (9.0-27.0)</td> <td>14.0 (7.0–25.0)</td> <td>0.460</td>	Emergency observation time (h) Median (Q1-Q3)	19.0 (9.0-27.0)	14.0 (7.0–25.0)	0.460	
<text></text>	Transfusion of red blood cells, n (%)			0.157	
Yes967 (93.7%)97.0%,97.0%,Transfusion of relation) Median (QI-Q3)29.00-4.0)3.7 (0.0-6.0)0.06Transfusion of plasma, n (%)42.07.0%,15.05.0%,0.001No62.07.0%,0.02.0%,0.02.0%,0.001Transfusion of plasma (ml) Median (QI-Q3)15.7 (0.0-200.0)27.3 (0.0-400.0)0.001Transfusion of rypercipitate, n (%)5.7 (0.0-200.0)80.27%,0.001Transfusion of platelets, n (%)15.7 (0.0-200.0)80.27%,0.001Yes15.40%81.02%,0.002%,0.002%,Transfusion of platelets, n (%)10.0%,10.0%,0.002%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,10.0%,10.0%,10.0%,Yes10.0%,<	No	383 (40.3%)	12 (29.3%)		
Transfusion of red blood cells (mJ) Median (Q1-Q3)2.9 (0.0-4.0)3.7 (0.0-6.0)0.061Transfusion of plasma, n (%)642 (67.6%)15 (36.6%)No640 (32.4%)66 (3.4%)Transfusion of plasma (mJ) Median (Q1-Q3)153.7 (0.0-200.0)2.72 (0.0-400.0)<0.001	Yes	567 (59.7%)	29 (70.7%)		
Tansfusion of plasma, n (%)<<No642 (67.%)15 (36.%)Yes08 (32.%)26 (63.%)Tansfusion of plasma (n) Median (Q1-Q3)38 (32.%)26 (33.%)Tansfusion of ryoprecipitate, n (%)89 (94.6%)38 (92.7%)Yes16 (34.%)38 (92.7%)Tarsfusion of platelets, n (%)16 (34.%)31 (34.%)Yes19 (90.%)40 (97.6%)No04 (97.6%)19 (20.%)40 (97.6%)Yes19 (20.%)40 (97.6%)Comorbidities, n (%)19 (20.%)10 (20.%)Yes19 (20.%)13 (34.%) </td <td>Transfusion of red blood cells (ml) Median (Q1-Q3)</td> <td>2.9 (0.0-4.0)</td> <td>3.7 (0.0-6.0)</td> <td>0.066</td>	Transfusion of red blood cells (ml) Median (Q1-Q3)	2.9 (0.0-4.0)	3.7 (0.0-6.0)	0.066	
No642 (67.6%)15 (36.6%)Yes308 (32.4%)26 (3.4%)Transfusion of plasma (ml) Median (Q1-Q3)15.7 (0.0-20.00)26 (3.4%)Transfusion of ryopreipitate, n (%)38 (92.7%)38 (02.7%)Yes31 (5.4%)38 (02.7%)37.3%)Transfusion of platelets, n (%)31 (3.4%)3 (7.3%)Transfusion of platelets, n (%)31 (98.0%)40 (97.6%)Yes91 (98.0%)40 (97.6%)16 (97.6%)Concribidities, n (%)12 (4%)50.0%)Yes91 (98.0%)28 (68.3%)16 (97.6%)Concribidities, n (%)75 (82.8%)28 (68.3%)16 (97.6%)No16 (78.9%)28 (68.3%)16 (97.6%)No82 (92.8%)38 (92.7%)91.6%)No82 (92.8%)38 (92.7%)16 (97.6%)No82 (92.8%)38 (92.7%)16 (97.6%)No91 (93.6%)39 (95.1%)16 (97.6%)No92 (97.2%)39 (95.1%)16 (97.6%)No	Transfusion of plasma, <i>n</i> (%)			< 0.001	
Yes308 (32.4%)26 (63.4%)Transfusion of plasma (ml) Median (Q1-Q3)15.7 (0.0-200.0)27.32 (0.0-400.0)-0.001Transfusion of cryoprecipitat, n (%)5.7 (0.0-200.0)36 (02.7%)-0.001No89 (94.6%)38 (92.7%)-0.001Transfusion of platelets, n (%)10.20%)40 (97.6%)-0.001Yes031 (98.0%)40 (97.6%)-0.001Yes19 (20%)12.4%)-0.001Combidities, n (%)12.4%)-0.001-0.001Combidities, n (%)26 (68.3%)-0.001Combidities, n (%)28 (68.3%)-0.001Chronic liver diseases767 (82.8%)28 (68.3%)-0.001No63 (17.2%)13 (31.7%)-0.001No82 (92.8%)36 (92.7%)-0.001Pisetes68 (29.2%)36 (92.7%)-0.001No82 (80.6%)36 (82.7%)-0.001No82 (80.6%)36 (87.8%)-0.001No82 (80.6%)36 (87.8%)-0.001No82 (80.6%)36 (87.8%)-0.001No82 (80.6%)36 (92.7%)-0.001No82 (80.6%)36 (92.7%)-0.001No90 (95.1%)-0.001-0.001No90 (92.5%)90 (95.1%)-0.001No90 (92.5%)90 (95.1%)-0.001No90 (92.5%)90 (95.1%)-0.001No90 (92.5%)90 (95.1%)-0.001No90 (90 (92.5%)90 (90.5%)-0.001No<	No	642 (67.6%)	15 (36.6%)		
Transfusion of plasma (ml) Median (Q1-Q3)153.7 (0.0-200.0)273.2 (0.0-400.0)<0011Transfusion of cryoprecipitate, n (%)899 (94.6%)38 (92.7%)58Yes51.6%)38 (92.7%)78Transfusion of platelets, n (%)10.5%)0.0816Yes931 (98.0%)40 (97.6%)78Yes19 (2.0%)1 (2.4%)10.1%)Comorbidities, n (%)787 (82.8%)28 (68.3%)78Yes787 (82.8%)28 (68.3%)78Yes10.7%)31.7%)78No882 (92.8%)38 (92.7%)78Yes68 (72%)3 (7.3%)78Yes23 (66.6%)36 (87.8%)78Yes127 (13.4%)5 (12.2%)16.1%)Yes34 (36.6%)3 (95.1%)74Yes34 (36.6%)3 (95.1%)74Yes34 (36.6%)3 (95.1%)74Yes34 (30.2%)24.9%)74.9%)Yes34 (30.2%)3 (92.7%)74.9%)Yes34 (30.2%)3 (92.7%)74.9%)Yes36 (92.5%)3 (92.7%)74.9%)Yes36 (92.5%)3 (92.7%)74.9%)Yes36 (92.5%)3 (92.7%)74.9%)Yes36 (92.7%)3 (92.7%)74.9%)Yes36 (92.7%)3 (92.7%)74.9%)Yes36 (92.7%)3 (92.7%)74.9%)Yes36 (92.7%)3 (92.7%)74.9%)Yes36 (92.7%)36.9%)74.9%)Yes	Yes	308 (32.4%)	26 (63.4%)		
Transfusion of cryoprecipitate, n (%)0.5900.590No590 (94.6%)38 (92.7%)38 (92.7%)Yes51 (54.%)3 (7.3%)38 (92.7%)Transfusion of platelets, n (%)931 (98.0%)40 (97.6%)No931 (98.0%)1 (24.%)38 (92.7%)Comorbidities, n (%)1 (24.%)50 (10.1%)Comorbidities, n (%)1 (24.%)50 (10.1%)Comorbidities, n (%)1 (24.%)50 (10.1%)No787 (82.8%)28 (68.3%)50 (10.1%)No82 (92.8%)38 (92.7%)50 (10.1%)No82 (92.8%)38 (92.7%)50 (10.1%)No82 (92.8%)36 (92.7%)50 (10.1%)No82 (92.8%)36 (92.7%)50 (10.1%)No82 (92.8%)36 (92.7%)50 (10.1%)No82 (92.8%)36 (92.7%)50 (10.1%)No916 (96.4%)36 (92.7%)50 (10.1%)No916 (96.4%)36 (92.7%)50 (10.1%)No916 (96.4%)36 (92.7%)50 (10.1%)No916 (96.4%)36 (92.1%)50 (10.1%)No916 (96.4%)36 (92.1%)50 (10.1%)No916 (96.2%)39 (95.1%)50 (10.1%)No92 (97.2%)39 (95.1%)50 (10.1%)No92 (Transfusion of plasma (ml) Median (Q1–Q3)	153.7 (0.0-200.0)	273.2 (0.0-400.0)	< 0.001	
No889 (94.%) $38 (92.\%)$ Yes $51 (5.4\%)$ $3 (7.3\%)$ Transfusion of platelets, n (%) $31 (98.0\%)$ $40 (97.6\%)$ Yes $931 (98.0\%)$ $40 (97.6\%)$ Yes $19 (2.0\%)$ $1 (2.4\%)$ Comrobidities, n (%) $1 (2.4\%)$ $00 (97.6\%)$ Chronic liver diseases $00 (97.6\%)$ $00 (97.6\%)$ No $787 (82.8\%)$ $28 (68.3\%)$ Yes $16 (17.2\%)$ $13 (31.7\%)$ Diabetes $00 (97.6\%)$ $38 (92.7\%)$ No $882 (92.8\%)$ $38 (92.7\%)$ No $882 (92.8\%)$ $38 (92.7\%)$ Yes $68 (7.2\%)$ $3 (7.3\%)$ No $823 (86.6\%)$ $30 (95.1\%)$ No $823 (86.6\%)$ $51 (12.9\%)$ No $916 (96.4\%)$ $39 (95.1\%)$ Yes $34 (3.6\%)$ $24.9\%)$ Yes $32 (97.2\%)$ $39 (95.1\%)$ No $923 (97.2\%)$ $39 (95.1\%)$ Yes $21 (2.8\%)$ $24.9\%)$ No $92 (92.5\%)$ $39 (95.1\%)$ Yes $90 (95.2\%)$ $90 (95.2\%)$ Yes $90 (95.2\%)$ $39 (95.1\%)$ Yes $90 (95.2\%)$ $90 (95.1\%)$ Yes $90 (95.2\%)$ $90 (95.2\%)$ Yes $90 (95.2\%)$ $90 (95.2\%)$	Transfusion of cryoprecipitate, <i>n</i> (%)			0.590	
Yes51 (5.4%)3 (7.3%)Transfusion of platelets, n (%)0.845No931 (98.0%)40 (97.6%)Yes19 (2.0%)1 (2.4%)Comorbidities, n (%)1 (2.4%)0.000Chronic liver disease0.017No787 (82.8%)28 (68.3%)Yes13 (17.2%)28 (68.3%)States13 (17.2%)3 (3.1%)Diabetes13 (3.1%)0.000No882 (92.8%)38 (92.7%)Yes68 (7.2%)3 (7.3%)No823 (86.6%)3 (7.3%)Yes21 (3.4%)5 (2.2%)No916 (96.4%)3 (95.1%)Yes34 (3.6%)2 (4.9%)No923 (97.2%)39 (95.1%)Yes21 (2.8%)2 (4.9%)No923 (97.2%)39 (95.1%)Yes21 (2.8%)3 (9.2%)Yes21 (2.8%)3 (9.2%)Yes21 (2.8%)3 (9.2%)Yes14 (4.8%)3 (7.3%)	No	899 (94.6%)	38 (92.7%)		
Transfusion of platelets, n (%)081No931 (98.0%)40 (97.6%)Yes19 (2.0%)1 (2.4%)Comorbidities, n (%)10.17Chronic liver diseases787 (82.8%)28 (68.3%)Yes13 (31.7%)13 (31.7%)Yes13 (31.7%)0.96No882 (92.8%)38 (92.7%)No86 (7.2%)38 (92.7%)Yes66 (87.8%)0.97Yes127 (13.4%)5 (12.2%)No823 (86.6%)36 (87.8%)Yes127 (13.4%)5 (12.2%)Stroke127 (13.4%)2 (4.9%)No916 (96.4%)39 (95.1%)No916 (96.4%)39 (95.1%)Yes34 (3.6%)24.9%)Yes23 (97.2%)92 (9.1%)Yes23 (97.2%)36 (97.9%)Yes23 (97.2%)36 (92.7%)Yes23 (97.2%)36 (92.7%)Yes24.9%)36 (92.7%)Yes24.9%)36 (92.7%)Yes24.9%)36 (92.7%)Yes46 (4.8%)37 (3%)	Yes	51 (5.4%)	3 (7.3%)		
No931 (98.0%)40 (97.6%)Yes19 (2.0%)1 (2.4%)Comorbidities, n (%)	Transfusion of platelets, <i>n</i> (%)			0.845	
Yes 19 (2,0%) 12 (2,4%) Comorbidities, n (%) 0 0.017 Chronic liver diseases 0.017 No 787 (82.8%) 28 (68.3%) Yes 13 (31.7%) 13 (31.7%) Diabetes 13 (31.7%) 0.069 No 882 (92.8%) 38 (92.7%) Yes 68 (7.2%) 3 (7.3%) Yes 3 (7.3%) 0.829 No 82 (92.8%) 3 (68.8%) Yes 3 (7.3%) 0.829 No 82 (92.8%) 3 (7.3%) Yes 3 (66.6%) 3 (7.3%) No 82 (92.8%) 3 (67.8%) Yes 127 (13.4%) 5 (12.2%) No 916 (96.4%) 3 (95.1%) Yes 34 (3.6%) 2 (4.9%) No 916 (96.4%) 3 (92.5%) No 2 (4.9%) 0.449 No 2 (4.9%) 0.449 No 2 (92.9%) 3 (92.5%) Yes 2 (92.9%) 3 (92.5%) No 2 (92.9%) 3 (92.5%) Yes	No	931 (98.0%)	40 (97.6%)		
Concritities, n (%) 0.017 Chronic liver diseases 787 (82.8%) 28 (68.3%) Yes 163 (72.9%) 13 (37.9%) Diabets 13 (37.9%) 9.06 No 882 (92.8%) 38 (92.7%) Yes 68 (72.9%) 30 (7.3%) Yes 68 (72.9%) 36 (87.8%) Yes 323 (86.6%) 36 (87.8%) Yes 127 (13.4%) 5 (12.2%) No 123 (96.6%) 39 (95.1%) Yes 16 (66.4%) 39 (95.1%) Yes 34 (36.6%) 2 (4.9%) No 120 (92.5%) 39 (95.1%) Yes 323 (97.2%) 39 (95.1%) Yes 94 (95.2%) 38 (92.7%)	Yes	19 (2.0%)	1 (2.4%)		
Chronic liver diseases0.017No787 (82.8%)28 (68.3%)Yes163 (17.2%)13 (31.7%)Diabets	Comorbidities, n (%)				
No 787 (82.8%) 28 (68.3%) Yes 13 (31.7%) Diabets 13 (31.7%) No 882 (92.8%) 38 (92.7%) Yes 68 (7.2%) 38 (92.7%) Hypertension 68 (7.2%) 37.3%) No 32 (86.6%) 3.6 (87.8%) Yes 127 (13.4%) 5 (12.2%) No 916 (96.4%) 39 (95.1%) Yes 34 (3.6%) 2 (4.9%) No 916 (96.4%) 39 (95.1%) Yes 34 (3.6%) 2 (4.9%) No 923 (97.2%) 39 (95.1%) Yes 27 (2.8%) 2 (4.9%) No 923 (97.2%) 39 (95.1%) Yes 2 (4.9%) 2 (4.9%) Yes 904 (95.2%) 38 (92.7%)	Chronic liver diseases			0.017	
Yes163 (17.2%)13 (31.7%)Diabets0.969No882 (92.8%)38 (92.7%)Yes68 (7.2%)3 (7.3%)Hypertension23 (86.6%)3 (6 (8.8%)Yes127 (13.4%)5 (12.2%)Yes127 (13.4%)5 (12.2%)Stroke16 (96.4%)39 (95.1%)Yes34 (3.6%)2 (4.9%)Yes23 (97.2%)39 (95.1%)Yes23 (97.2%)39 (95.1%)Yes23 (97.2%)39 (95.1%)Yes27 (2.8%)2 (4.9%)Yes20 (92.5%)38 (92.7%)	No	787 (82.8%)	28 (68.3%)		
Diabetes 0.969 No 882 (92.8%) 38 (92.7%) Yes 68 (7.2%) 3(7.3%) Hypertension 82 (86.6%) 36 (87.8%) No 823 (86.6%) 36 (87.8%) Yes 127 (13.4%) 5 (12.2%) Stroke 127 (13.4%) 5 (12.2%) No 916 (96.4%) 39 (95.1%) Yes 34 (3.6%) 2 (4.9%) No 923 (97.2%) 39 (95.1%) Yes 20 (4.9%) 4.449 Yes 20 (4.9%) 0.474 No 923 (97.2%) 39 (95.1%) Yes 20 (4.9%) 0.474 Yes 20 (4.9%) 0.474 Yes 904 (95.2%) 38 (92.7%)	Yes	163 (17.2%)	13 (31.7%)		
No 882 (92.8%) 38 (92.7%) Yes 68 (7.2%) 3 (7.3%) Hypertension	Diabetes			0.969	
Yes 68 (7.2%) 3 (7.3%) Hypertension	No	882 (92.8%)	38 (92.7%)		
Hypertension 0.829 No 823 (86.6%) 36 (87.8%) Yes 127 (13.4%) 5 (12.2%) Stroke 0.663 No 916 (96.4%) 39 (95.1%) Yes 34 (3.6%) 2 (4.9%) Hematological system diseases 0.449 No 923 (97.2%) 39 (95.1%) Yes 27 (2.8%) 2 (4.9%) Tumor 0.474 No 904 (95.2%) 38 (92.7%)	Yes	68 (7.2%)	3 (7.3%)		
No 823 (86.6%) 36 (87.8%) Yes 127 (13.4%) 5 (12.2%) Stroke 0.663 No 916 (96.4%) 39 (95.1%) Yes 34 (3.6%) 2 (4.9%) Hematological system diseases 0.449 No 923 (97.2%) 39 (95.1%) Yes 27 (2.8%) 2 (4.9%) No 904 (95.2%) 38 (92.7%) No 904 (95.2%) 38 (92.7%)	Hypertension			0.829	
Yes127 (13.4%)5 (12.2%)Stroke0.663No916 (96.4%)39 (95.1%)Yes34 (3.6%)2 (4.9%)Hematological system diseases0.449No923 (97.2%)39 (95.1%)Yes27 (2.8%)2 (4.9%)Tumor0.474No904 (95.2%)38 (92.7%)Yes46 (4.8%)3 (7.3%)	No	823 (86.6%)	36 (87.8%)		
Stroke 0.663 No 916 (96.4%) 39 (95.1%) Yes 34 (3.6%) 2 (4.9%) Hematological system diseases 0.449 No 923 (97.2%) 39 (95.1%) Yes 27 (2.8%) 2 (4.9%) Tumor 0.474 No 904 (95.2%) 38 (92.7%) Yes 46 (4.8%) 3 (7.3%)	Yes	127 (13.4%)	5 (12.2%)		
No 916 (96.4%) 39 (95.1%) Yes 34 (3.6%) 2 (4.9%) Hematological system diseases 0.449 No 923 (97.2%) 39 (95.1%) Yes 27 (2.8%) 2 (4.9%) Tumor 0.474 No 904 (95.2%) 38 (92.7%) Yes 46 (4.8%) 3 (7.3%)	Stroke			0.663	
Yes 34 (3.6%) 2 (4.9%) Hematological system diseases 0.449 No 923 (97.2%) 39 (95.1%) Yes 27 (2.8%) 2 (4.9%) Tumor 27 (2.8%) 2 (4.9%) No 904 (95.2%) 38 (92.7%) Yes 46 (4.8%) 3 (7.3%)	No	916 (96.4%)	39 (95.1%)		
Hematological system diseases 0.449 No 923 (97.2%) 39 (95.1%) Yes 27 (2.8%) 2 (4.9%) Tumor 0.474 No 904 (95.2%) 38 (92.7%) Yes 46 (4.8%) 3 (7.3%)	Yes	34 (3.6%)	2 (4.9%)		
No 923 (97.2%) 39 (95.1%) Yes 27 (2.8%) 2 (4.9%) Tumor 0.474 No 904 (95.2%) 38 (92.7%) Yes 46 (4.8%) 3 (7.3%)	Hematological system diseases			0.449	
Yes 27 (2.8%) 2 (4.9%) Tumor 0.474 No 904 (95.2%) 38 (92.7%) Yes 46 (4.8%) 3 (7.3%)	No	923 (97.2%)	39 (95.1%)		
Tumor 0.474 No 904 (95.2%) 38 (92.7%) Yes 46 (4.8%) 3 (7.3%)	Yes	27 (2.8%)	2 (4.9%)		
No 904 (95.2%) 38 (92.7%) Yes 46 (4.8%) 3 (7.3%)	Tumor			0.474	
Yes $46(4.8\%)$ $3(7.3\%)$	No	904 (95.2%)	38 (92.7%)		
	Yes	46 (4.8%)	3 (7.3%)		

(Continued)

Table 1 (continued)

Variable	Death in emergency department		
	No $(n = 950)$	Yes $(n = 41)$	
Heart failure, coronary heart disease			0.615
No	912 (96.0%)	40 (97.6%)	
Yes	38 (4.0%)	1 (2.4%)	
Respiratory failure			0.760
No	933 (98.2%)	40 (97.6%)	
Yes	17 (1.8%)	1 (2.4%)	
Kidney failure			0.478
No	904 (95.2%)	40 (97.6%)	
Yes	46 (4.8%)	1 (2.4%)	
Receive endoscopy			0.345
No	579 (60.9%)	28 (68.3%)	
Yes	371 (39.1%)	13 (31.7%)	
Source of bleeding according to endoscopic report			
Peptic ulcer	178 (48.0%)	7 (53.8%)	0.677
Gastric	52 (14.0%)	2 (15.4%)	0.889
Duodenal	117 (31.5%)	3 (23.1%)	0.518
Stomal	9 (2.4%)	2 (15.4%)	0.006
Gastroesophageal varices	110 (29.6%)	3 (23.1%)	0.609
Mallory-Weiss tears	11 (3.0%)	0 (0.0%)	0.529
Erosive gastritis or esophagitis	35 (9.4%)	0 (0.0%)	0.245
Neoplasms	13 (3.5%)	2 (15.4%)	0.030
Other	24 (6.5%)	1 (7.7%)	0.861

Notes:

The definition of comorbidities. Renal failure: previous history of kidney failure, on dialysis or GFR < 15 ml/min/1.73 m²; Respiratory failure: $PO_2 < 60$ mmHg or $SO_2 < 90\%$ on room air; Heart failure: current or past clinical symptoms (limitation of activity, fatigue and dyspnea or orthopnea), signs (edema, elevated jugular venous pressure, rales, or S3 gallop), or radiologic evidence of pulmonary congestion.

HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; RBC, red blood cell; HCT, hematocrit; HB, hemoglobin; PLT, platelet count; CRP, C-reactive protein; PT, prothrombin time; INR, international normalized ratio; ALT, alanine aminotransferase; AST, glutamic oxaloacetic transaminase; BUN, blood urea nitrogen; ALB, albumin; A/G, albumin /globulin ratio; GFR, glomerular filtration rate.

distress syndrome, and pneumonia (*Zhang et al., 2017*), which resulted in a relatively higher mortality rate among these patients. D-dimer, as a fibrinolytic activity monitor, is generally used to evaluate the overall fibrinolytic condition in UGIB patients (*Yue et al., 2020*). Patients were considered to have hyperfibrinolysis if they concomitantly had high values of D-dimer and t-PA activity (*Violl et al., 1996*). Thus D-dimer is a stronger predictor for severity and prognosis both in Nonvariceal UGIB and variceal UGIB (*Primignani et al., 2008*; *Yue et al., 2020*).

Albumin has multiple biological characteristics, and hypoalbuminemia is a risk factor of mortality in certain diseases. The correlation between hypoalbuminemia and the prognosis of UGIB has also been reported (*Lyles, Elliott & Rockey, 2014; Bunchorntavakul, Yodket & Singhasena, 2017*). Many studies used the receiver operating characteristic (ROC) curve to find the best value of albumin for predicting mortality. Lower than 3.2 or



Figure 2 Predictors selection based on the least absolute shrinkage and selection operator (LASSO) regression method. (A) Tuning parameter (lambda) selection in the LASSO regression used 10-fold cross-validation. Binomial deviance was plotted versus log (lambda). The dotted vertical lines were drawn at the optimal values by using the 1-SE criteria. (B) LASSO regression coefficient profiles of variables.

Figure 2 (continued)

A coefficient profile plot was created against the log (lambda) sequence. Dotted vertical lines were drawn at the optimal values by using the 1-SE criteria. In the present study, predictors were chosen according to the 1-SE criteria, a total of five non-zero coefficients were filtered and used to construct the predictive model. SE, standard error. Full-size DOI: 10.7717/peerj.11656/fig-2

Table 2 Logistic regression model and the Odds ratio of predictors.						
Variable	β	OR (95% CI)	Р			
Transfusion of plasma, yes	1.163	2.913 [1.315-6.453]	0.008			
ALB (g/L)	-0.089	0.918 [0.857-0.983]	0.014			
Potassium (mmol/L)	0.779	2.020 [1.386-2.945]	0.000			
Age (years)	0.036	1.037 [1.007-1.068]	0.015			
D-dimer (µg/L)	0.001	1 [1-1.001]	0.003			
NT /						

Notes:

Logistic regression model: $-7.335 + 1.163 \times$ (Transfusion of plasma, yes) $-0.089 \times$ ALB (g/L) $+ 0.779 \times$ Potassium (mmol/L) $+ 0.036 \times$ Age (years) $+ 0.001 \times$ D-dimer (µg/L).

ALB, albumin; CI, confidence interval; OR, odds ratio

2.6 was used as criteria for hypoalbuminemia and were considered to be independent predictors of death (*Gonzalez-Gonzalez et al., 2011, 2016; Chandnani et al., 2019*). Our study showed that the lower the albumin, the greater the risk of death in the ED. With increasing age, the function of the human body gradually decreases, and comorbidities also increase. Therefore, advanced age is a risk factor for the prognosis of various diseases (*Rajan et al., 2019*). In the present study, the risk of death increases with age.

Interestingly, high serum potassium, which has never been clearly described as an outcome predictor of UGIB, was found to be an independent predictor for death in ED. Mortality risk progressively increased with dyskalemia in patients with and without heart failure, chronic kidney disease, and/or diabetes (*Collins et al., 2017*). Many studies have shown that serum potassium concentration correlates with the severity of cirrhosis, and mortality was also significantly higher in patients with hyperkalemia (*Uslan, Olt & Eminler, 2015; Maiwall et al., 2016*). Accordingly, it is likely that serum potassium can be another valuable predictor for death in patients presenting with UGIB.

There are many different scoring systems available to stratify patients with AUGIB at risk of rebleeding or death and to predict the need for clinical interventions such as transfusion and endoscopic therapy. GBS was established to identify patients at low or high risk of needing treatment (*Blatchford, Murray & Blatchford, 2000*), while RS and AIMS65 were developed to predict in-hospital mortality (*Rockall et al., 1996; Saltzman et al., 2011*). However, only some scores from these models are suitable for ED, and the results are inconsistent. The most widely studied scores are PERS, GBS, mGBS, and AIMS65 (*Rout et al., 2019; Tham & Stanley, 2019*). When compared with RS and PERS, GBS has been shown to be the best for predicting intervention or death (*Park et al., 2016; Stanley et al., 2017*). For predicting in-hospital mortality, other studies have shown that the area under the ROC curve (AUROC) of AIMS65 is superior to or similar to the GBS, RS, and PERS for patients with AUGIB (*Yaka et al., 2015; Budimir et al., 2016; Martinez-Cara*)





Models	Original AUC	95% CI	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	P ^b	Corrected AUC ^a	95% CI	P ^b
Nomogram	0.847	[0.794-0.900]	0.947	0.604	0.099	0.996		0.858	[0.806-0.898]	
GBS	0.647	[0.561-0.733]	0.650	0.632	0.076	0.974	< 0.001	0.638	[0.542-0.715]	< 0.001
MGBS	0.678	[0.599-0.757]	0.553	0.692	0.076	0.971	< 0.001	0.693	[0.611-0.769]	< 0.001
PERS	0.681	[0.606-0.756]	0.763	0.496	0.064	0.979	< 0.001	0.696	[0.618-0.779]	< 0.001
AIMS65	0.567	[0.483-0.651]	0.889	0.209	0.050	0.976	< 0.001	0.573	[0.471-0.679]	< 0.001

Table 3 AUC, sensitivity, specificity, positive predictive value, negative predictive value of different prognostic models to predict mortality risk in patients with AUGIB.

Notes:

^a Using bootstrap 500.

^b Compared with the predictive model that we developed.

AUGIB, acute upper gastrointestinal bleeding; GBS, Glasgow-Blatchford bleeding score; MGBS, modified Glasgow-Blatchford bleeding score; PERS, Pre-Endoscopic Rockall Score; AUC, area under the curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.



Figure 4 Nomogram for estimation of patient's risk of death due to acute upper gastrointestinal bleeding (AUGIB) in the emergency department or within 24 h after leaving the emergency department. First, score each predictor value of an individual using the top scale. Second, sum up all the scores and identify the corresponding score on the scale. Finally, the corresponding risk of death in the emergency department or within 24 h after leaving the emergency department for the given patient is on the lowest rule. For example, a patient received transfusion of plasma in emergency department (10 point), D-dimer 5,000 μ g/L (15 point), potassium 5 mmol/L (30 point), albumin 30 g/L (20 point) and 90 years old (30 point), than the total score is 105 point and the risk of death is about 50%. Full-size DOI: 10.7717/peerj.11656/fig-4



Figure 5 Calibration curve of the predictive model. It shows a good fit between the predicted risk of death and observed outcomes in patients with acute upper gastrointestinal bleeding. The red solid line represents an ideal predictive model, and the solid black line shows the actual performance of the predictive model. The yellow shadow represents a 95% confidence interval. The model overestimated mortality risk in patients with an predicted mortality great than 8%.

Full-size 🖾 DOI: 10.7717/peerj.11656/fig-5

et al., 2016; Tang et al., 2018; Kim, Choi & Shin, 2019; Robertson et al., 2020). However, the predictive effects of these scoring systems for death ranged from 0.56 to 0.91 (Uslan, Olt & Eminler, 2015; Maiwall et al., 2016; Collins et al., 2017; Rajan et al., 2019; Rout et al., 2019; Tham & Stanley, 2019; Shung et al., 2020). The machine learning model developed by Shung et al., which aimed to identify patients meeting a composite endpoint of hospital-based intervention or death within 30 days, performed better than the GBS, admission-RS, and AIMS65 (Shung et al., 2020). However, an app is required in order to access this tool. In addition, most of these studies have focused on predicting hospital mortality or death within 30 days. An effective emergency death risk assessment model may be more valuable to emergency care providers. In our study, we included the parameters considered in the established scoring system and added other parameters that may be relevant to the prognosis, such as CRP, coagulation function tests, and laboratory test results that reflect the functions of important organs such as the liver and kidney (Makhlouf & Morsy, 2012; Tomizawa et al., 2014; Bunchorntavakul, Yodket & Singhasena, 2017). Also, we included transfusion of blood. Among the existing models, our results show that PERS is most effective for predicting in-ED mortality. Nevertheless, our new model outperformed PERS in both the original AUC and corrected AUC.



Figure 6 Decision curve analysis of the predictive model. Net benefit was produced against the high-risk threshold. The red solid line represents the predicted estimates. The decision curve indicates that when the threshold probability was within 3–76%, using this model in decision-making benefitted patient outcomes compared with either treat-all or treat-none strategies. Full-size DOI: 10.7717/peerj.11656/fig-6

Nomograms are graphical depictions of individual-level prognosis predictions and have been shown to be more accurate than conventional models for predicting prognosis (*Balachandran et al., 2015; Cooperman et al., 2016; Huang et al., 2016; Touijer & Scardino, 2009*). We established a nomogram based on five predictors including four clinical patient characteristics, which can be readily obtained in clinical settings, and one medical intervention that can be used for the better management of patients. LASSO is a statistical formula mainly used for feature selection and regularization of data model. The LASSO method regularizes the parameters of the model by shrinking the regression coefficient and reduces some of them to zero. The feature selection phase occurs after the shrinkage, where each non-zero value is selected for use in the model (*Chang et al., 2021*). LASSO, which is considered superior to the conventional approach of choosing predictors, is commonly used in studies with a small sample size and a large number of predictors (*Huang et al., 2016*).

This study is the first to construct a nomogram that combines both patient characteristics and clinical interventions for predicting the clinical outcome of patients presenting with AUGIB at an ED. The nomogram shows a good discriminative ability. However, this study has several limitations. First, this was a single-center retrospective study, and therefore its clinical usefulness remains to be assessed through external validation. Second, we only used the first available data obtained at the time of emergency admission for each patient, and therefore did not consider any subsequent changes. Thus, further research is required to validate this model. Third, not all patients underwent endoscopy and the diagnosis of UGIB was mainly based on symptoms, signs, and laboratory tests. Although patients' electronic medical records were carefully reviewed, it is possible that the exact site of the bleeding of some patients may not be able to be identified. Moreover, we did not collect creatinine clearance and electrocardiogram, which maybe associated with blood potassium concentration. Therefore, we could not determine the correlation between these factors and death. However, we built a model with good performance. The addition of other variables would not significantly improve the prediction effect of the model. Finally, the outcome in our study was emergency mortality risk. Whether this model is applicable to predict in-hospital death, needs further research.

CONCLUSIONS

We established and internally validated a nomogram to predict mortality among patients with AUGIB presenting at an ED. The nomogram was based on five readily available clinical predictors and details of clinical interventions. This model may be of value for individual risk assessments and for guiding staff in selecting interventions that are most likely to improve patient outcomes.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by the Youth Research Fund of Jinhua Municipal Central Hospital (No. 2016-02-06) to Han Zheng. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors: Youth Research Fund of Jinhua Municipal Central Hospital: 2016-02-06.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Lan Chen conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Han Zheng conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

• Saibin Wang conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

Ethics Committee of Jinhua Municipal Central Hospital approved this research (No.16–32).

Data Availability

The following information was supplied regarding data availability:

The raw measurements are available in the Supplemental File.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/ peerj.11656#supplemental-information.

REFERENCES

- Abougergi MS, Charpentier JP, Bethea E, Rupawala A, Kheder J, Nompleggi D, Liang P, Travis AC, Saltzman JR. 2016. A prospective, multicenter study of the AIMS65 score compared with the glasgow-blatchford score in predicting upper gastrointestinal hemorrhage outcomes. *Journal of Clinical Gastroenterology* 50(6):464–469 DOI 10.1097/MCG.000000000000395.
- Balaban DV, Strambu V, Florea BG, Cazan AR, Bratucu M, Jinga M. 2014. Predictors for in-hospital mortality and need for clinical intervention in upper GI bleeding: a 5-year observational study. *Chirurgia* 109:48–54.
- Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. 2015. Nomograms in oncology: more than meets the eye. *Lancet Oncology* 16(4):e173–e180 DOI 10.1016/S1470-2045(14)71116-7.
- Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, Leontiadis GI, Abraham NS, Calvet X, Chan FKL, Douketis J, Enns R, Gralnek IM, Jairath V, Jensen D, Lau J, Lip GYH, Loffroy R, Maluf-Filho F, Meltzer AC, Reddy N, Saltzman JR, Marshall JK, Bardou M. 2019. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. *Annals of Internal Medicine* 171(11):805–822 DOI 10.7326/M19-1795.
- Blatchford O, Murray WR, Blatchford M. 2000. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. *Lancet* 356(9238):1318–1321 DOI 10.1016/S0140-6736(00)02816-6.
- Budimir I, Gradiser M, Nikolic M, Barsic N, Ljubicic N, Kralj D, Budimir IJ. 2016. Glasgow Blatchford, pre-endoscopic Rockall and AIMS65 scores show no difference in predicting rebleeding rate and mortality in variceal bleeding. *Scandinavian Journal of Gastroenterology* 51(11):1375–1379 DOI 10.1080/00365521.2016.1200138.
- Bunchorntavakul C, Yodket Y, Singhasena N. 2017. Clinical characteristics, treatment outcomes and risk assessment of patients with acute upper gastrointestinal bleeding in Rajavithi Hospital. *Thailand Journal of the Medical Association of Thailand = Chotmaihet Thangphaet* 100(Suppl. 1):S104–S115.

- Chandnani S, Rathi P, Sonthalia N, Udgirkar S, Jain S, Contractor Q, Jain S, Singh AK. 2019. Comparison of risk scores in upper gastrointestinal bleeding in western India: a prospective analysis. *Indian Journal of Gastroenterology* 38(2):117–127 DOI 10.1007/s12664-019-00951-w.
- Chang C, Sun X, Wang G, Yu H, Zhao W, Ge Y, Duan S, Qian X, Wang R, Lei B, Wang L, Liu L, Ruan M, Yan H, Liu C, Chen J, Xie W. 2021. A machine learning model based on PET/CT radiomics and clinical characteristics predicts ALK rearrangement status in lung adenocarcinoma. *Frontiers in Oncology* 11:603882 DOI 10.3389/fonc.2021.603882.
- **Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, Bushinsky DA. 2017.** Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. *American Journal of Nephrology* **46(3)**:213–221 DOI 10.1159/000479802.
- **Cooperman NA, Lu SE, Richter K, Bernstein SL, Williams JM. 2016.** Influence of psychiatric and personality disorders on smoking cessation among individuals in opiate dependence treatment. *Journal of Dual Diagnosis* **12(2)**:118–128 DOI 10.1080/15504263.2016.1172896.
- Gaduputi V, Abdulsamad M, Tariq H, Rafeeq A, Abbas N, Kumbum K, Chilimur S. 2014. Prognostic value of AIMS65 Score in cirrhotic patients with upper gastrointestinal bleeding. *Gastroenterology Research and Practice* 2014:787256 DOI 10.1155/2014/787256.
- Gonzalez-Gonzalez JA, Vazquez-Elizondo G, Garcia-Compean D, Gaytan-Torres JO, Flores-Rendon AR, Jaquez-Quintana JO, Garza-Galindo AA, Cardenas-Sandoval MG, Maldonado-Garza HJ. 2011. Predictors of in-hospital mortality in patients with non-variceal upper gastrointestinal bleeding. *Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva* 103(4):196–203 DOI 10.4321/s1130-01082011000400005.
- Gonzalez-Gonzalez JA, Vazquez-Elizondo G, Monreal-Robles R, Garcia-Compean D,
 Borjas-Almaguer OD, Hernandez-Velazquez B, Maldonado-Garza HJ. 2016.
 Hypoalbuminemia in the outcome of patients with non-variceal upper gastrointestinal bleeding.
 Revista de Gastroenterologia de Mexico 81(4):183–189 DOI 10.1016/j.rgmx.2016.03.005.
- Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, Ma ZL, Liu ZY. 2016. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. *Journal of Clinical Oncology* 34(18):2157–2164 DOI 10.1200/JCO.2015.65.9128.
- Kim MS, Choi J, Shin WC. 2019. AIMS65 scoring system is comparable to Glasgow-Blatchford score or Rockall score for prediction of clinical outcomes for non-variceal upper gastrointestinal bleeding. *BMC Gastroenterology* **19(1)**:136 DOI 10.1186/s12876-019-1051-8.
- Ko IG, Kim SE, Chang BS, Kwak MS, Yoon JY, Cha JM, Shin HP, Lee JI, Kim SH, Han JH, Jeon JW. 2017. Evaluation of scoring systems without endoscopic findings for predicting outcomes in patients with upper gastrointestinal bleeding. *BMC Gastroenterology* 17(1):159 DOI 10.1186/s12876-017-0716-4.
- Lahiff C, Shields W, Cretu I, Mahmud N, McKiernan S, Norris S, Silke B, Reynolds JV, O'Toole D. 2012. Upper gastrointestinal bleeding: predictors of risk in a mixed patient group including variceal and nonvariceal haemorrhage. *European Journal of Gastroenterology & Hepatology* 24(2):149–154 DOI 10.1097/MEG.0b013e32834e37d6.
- Lyles T, Elliott A, Rockey DC. 2014. A risk scoring system to predict in-hospital mortality in patients with cirrhosis presenting with upper gastrointestinal bleeding. *Journal of Clinical Gastroenterology* **48(8)**:712–720 DOI 10.1097/MCG.0000000000014.

- Maiwall R, Kumar S, Sharma MK, Wani Z, Ozukum M, Sarin SK. 2016. Prevalence and prognostic significance of hyperkalemia in hospitalized patients with cirrhosis. *Journal of Gastroenterology and Hepatology* **31**(5):988–994 DOI 10.1111/jgh.13243.
- Makhlouf NA, Morsy KH. 2012. Renal failure after upper-gastrointestinal bleeding among cirrhotic patients in Upper Egypt. *Arab Journal of Gastroenterology* **13(3)**:139–144 DOI 10.1016/j.ajg.2012.08.003.
- Martinez-Cara JG, Jimenez-Rosales R, Ubeda-Munoz M, De Hierro ML, De Teresa J, Redondo-Cerezo E. 2016. Comparison of AIMS65, Glasgow–Blatchford score, and Rockall score in a European series of patients with upper gastrointestinal bleeding: performance when predicting in-hospital and delayed mortality. United European Gastroenterology Journal 4(3):371–379 DOI 10.1177/2050640615604779.
- Park SM, Yeum SC, Kim BW, Kim JS, Kim JH, Sim EH, Ji JS, Choi H. 2016. Comparison of AIMS65 score and other scoring systems for predicting clinical outcomes in Koreans with nonvariceal upper gastrointestinal bleeding. *Gut and Liver* 10(4):526–531 DOI 10.5009/gnl15153.
- Primignani M, Dell'Era A, Bucciarelli P, Bottasso B, Bajetta MT, De Franchis R, Cattaneo M.
 2008. High-D-dimer plasma levels predict poor outcome in esophageal variceal bleeding.
 Digestive and Liver Disease 40(11):874–881 DOI 10.1016/j.dld.2008.01.010.
- Rajan SS, Sawe HR, Iyullu AJ, Kaale DA, Olambo NA, Mfinanga JA, Weber EJ. 2019. Profile and outcome of patients with upper gastrointestinal bleeding presenting to urban emergency departments of tertiary hospitals in Tanzania. *BMC Gastroenterology* 19(1):212 DOI 10.1186/s12876-019-1131-9.
- Robertson M, Ng J, Abu SW, Swaine A, Skardoon G, Huynh A, Deshpande S, Low ZY, Sievert W, Angus P. 2020. Risk stratification in acute variceal bleeding: comparison of the AIMS65 score to established upper gastrointestinal bleeding and liver disease severity risk stratification scoring systems in predicting mortality and rebleeding. *Digestive Endoscopy* 32(5):761–768 DOI 10.1111/den.13577.
- Rockall TA, Logan RF, Devlin HB, Northfield TC. 1996. Risk assessment after acute upper gastrointestinal haemorrhage. *Gut* 38(3):316–321 DOI 10.1136/gut.38.3.316.
- Rout G, Sharma S, Gunjan D, Kedia S, Nayak B, Shalimar. 2019. Comparison of various prognostic scores in variceal and non-variceal upper gastrointestinal bleeding: a prospective cohort study. *Indian Journal of Gastroenterology* **38(2)**:158–166 DOI 10.1007/s12664-018-0928-8.
- Saltzman JR, Tabak YP, Hyett BH, Sun X, Travis AC, Johannes RS. 2011. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. *Gastrointestinal Endoscopy* 74(6):1215–1224 DOI 10.1016/j.gie.2011.06.024.
- Shung DL, Au B, Taylor RA, Tay JK, Laursen SB, Stanley AJ, Dalton HR, Ngu J, Schultz M, Laine L. 2020. Validation of a machine learning model that outperforms clinical risk scoring systems for Upper Gastrointestinal bleeding. *Gastroenterology* 158(1):160–167 DOI 10.1053/j.gastro.2019.09.009.
- Stanley AJ, Laine L, Dalton HR, Ngu JH, Schultz M, Abazi R, Zakko L, Thornton S, Wilkinson K, Khor CJ, Murray IA, Laursen SB. 2017. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. *BMJ* 356:i6432 DOI 10.1136/bmj.i6432.
- Subramaniam K, Spilsbury K, Ayonrinde OT, Latchmiah F, Mukhtar SA, Semmens JB, Leahy MF, Olynyk JK. 2016. Red blood cell transfusion is associated with further bleeding and

fresh-frozen plasma with mortality in nonvariceal upper gastrointestinal bleeding. *Transfusion* **56(4)**:816–826 DOI 10.1111/trf.13446.

- Tang Y, Shen J, Zhang F, Zhou X, Tang Z, You T. 2018. Scoring systems used to predict mortality in patients with acute upper gastrointestinal bleeding in the ED. *American Journal of Emergency Medicine* 36(1):27–32 DOI 10.1016/j.ajem.2017.06.053.
- Tham J, Stanley A. 2019. Clinical utility of pre-endoscopy risk scores in upper gastrointestinal bleeding. *Expert Review of Gastroenterology & Hepatology* 13(12):1161–1167 DOI 10.1080/17474124.2019.1698292.
- Tomizawa M, Shinozaki F, Hasegawa R, Togawa A, Shirai Y, Ichiki N, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. 2014. Reduced hemoglobin and increased C-reactive protein are associated with upper gastrointestinal bleeding. *World Journal of Gastroenterology* 20(5):1311–1317 DOI 10.3748/wjg.v20.i5.1311.
- Touijer K, Scardino PT. 2009. Nomograms for staging, prognosis, and predicting treatment outcomes. *Cancer* 115(S13):3107–3111 DOI 10.1002/cncr.24352.
- Uslan I, Olt S, Eminler AT. 2015. Which factors are predictive for mortality among hospitalized patients with Cirrhosis? *Hepatogastroenterology* **62**:1023–1026.
- Vickers AJ, Cronin AM, Elkin EB, Gonen M. 2008. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. *BMC Medical Informatics and Decision Making* 8(1):53 DOI 10.1186/1472-6947-8-53.
- Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C, Graupera I, Poca M, Alvarez-Urturi C, Gordillo J, Guarner-Argente C, Santaló M, Muñiz E, Guarner C.
 2013. Transfusion strategies for acute upper gastrointestinal bleeding. New England Journal of Medicine 368(1):11-21 DOI 10.1056/NEJMoa1211801.
- Violl F, Basili S, Ferro D, Quintarelli C, Alessandril C, Cordova C. 1996. Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. *Thrombosis and Haemostasi* 76(2):177–183 DOI 10.1055/s-0038-1650549.
- Wang S, Tu J, Dong K. 2019. Nomogram to predict postoperative PR in patients undergoing CT-guided transthoracic lung biopsy. *Journal of Thoracic Disease* 11(4):1705–1713 DOI 10.21037/jtd.2019.01.60.
- Yaka E, Yilmaz S, Dogan NO, Pekdemir M. 2015. Comparison of the Glasgow-Blatchford and AIMS65 scoring systems for risk stratification in upper gastrointestinal bleeding in the emergency department. *Academic Emergency Medicine* 22(1):22–30 DOI 10.1111/acem.12554.
- Yue W, Liu Y, Jiang W, Huang J, Liu J. 2020. Prealbumin and D-dimer as prognostic indicators for rebleeding in patients with nonvariceal upper gastrointestinal bleeding. *Digestive Diseases and Sciences* 66(6):1949–1956 DOI 10.1007/s10620-020-06420-1.
- Zhang LM, Li R, Zhao XC, Zhang Q, Luo XL. 2017. Increased transfusion of fresh frozen plasma is associated with mortality or worse functional outcomes after severe traumatic brain injury: a retrospective study. *World Neurosurgery* **104**:381–389 DOI 10.1016/j.wneu.2017.04.140.
- Zhou YJ, Zheng JN, Zhou YF, Han YJ, Zou TT, Liu WY, Braddock M, Shi KQ, Wang XD, Zheng MH. 2017. Development of a prognostic nomogram for cirrhotic patients with upper gastrointestinal bleeding. *European Journal of Gastroenterology & Hepatology* 29(10):1166–1173 DOI 10.1097/MEG.00000000000943.